Market Place
Sourcing Support
Vaccinex Secures $60M for Pepinemab Phase 2b Alzheimer`s Trial
23 Dec 2025 //
GLOBENEWSWIRE
Vaccinex to Report New Clinical Results at ASCO Meeting
27 May 2025 //
GLOBENEWSWIRE
AbTherx, Single Cell Tech, and Vaccinex Collaborate on ADC Tagert
13 May 2025 //
ACCESSWIRE
Vaccinex to Report New Data on Pepinemab at AACR Meeting
21 Apr 2025 //
GLOBENEWSWIRE
Vaccinex to Delist Common Stock from Nasdaq Stock Market
07 Mar 2025 //
GLOBENEWSWIRE
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
17 Dec 2024 //
GLOBENEWSWIRE
Vaccinex Reports Q3 2024 Financial Results & Corporate Update
18 Nov 2024 //
GLOBENEWSWIRE
Vaccinex Update on ActivMAb® Platform & SITC Presentation
07 Nov 2024 //
GLOBENEWSWIRE
Vaccinex Reports Immunity Benefit with Pepinemab at SITC Meeting
05 Nov 2024 //
GLOBENEWSWIRE
Vaccinex Reports SIGNAL-AD Data for Pepinemab at CTAD
31 Oct 2024 //
GLOBENEWSWIRE
Vaccinex To Report Efficacy Data For SIGNAL-AD Trial At CTAD
24 Oct 2024 //
GLOBENEWSWIRE
Vaccinex Announces $6.2M From Warrant Exercise
18 Sep 2024 //
GLOBENEWSWIRE
Vaccinex Reports Positive Phase 1b/2 Data For Pepinemab In Alzheimer`s
31 Jul 2024 //
GLOBENEWSWIRE
Vaccinex Reports Last Patient Visit In SIGNAL-AD Pepinemab Alzheimer`s Trial
06 Jun 2024 //
GLOBENEWSWIRE
Vaccinex Reports Q1 2024 Financial Results, Corporate Update
15 May 2024 //
GLOBENEWSWIRE
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
02 Apr 2024 //
GLOBENEWSWIRE
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering
27 Mar 2024 //
GLOBENEWSWIRE
Vaccinex Announces Agreements for Access to ActivMAb® Antigen Virus Technology
21 Feb 2024 //
GLOBENEWSWIRE
Vaccinex, Inc. Announces Reverse Stock Split
15 Feb 2024 //
GLOBENEWSWIRE
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
07 Feb 2024 //
GLOBENEWSWIRE
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance
04 Dec 2023 //
GLOBENEWSWIRE
Vaccinex Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Vaccinex Reports Benefit in Analyses from two Phase 2 Studies of Pepinemab
31 Oct 2023 //
GLOBENEWSWIRE
Vaccinex Reports Effect of Pepinemab Treatment in Neurodegenerative Diseases
26 Oct 2023 //
GLOBENEWSWIRE
Vaccinex Announces Pricing of $9.6 Million Public Offering
28 Sep 2023 //
GLOBENEWSWIRE
Vaccinex™s Next Generation ActivMAb® Technology Published in mAbs
28 Sep 2023 //
GLOBENEWSWIRE
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
27 Sep 2023 //
GLOBENEWSWIRE
Vaccinex Reports Groundbreaking Findings at Medical Conferences
26 Sep 2023 //
GLOBENEWSWIRE
Vaccinex, Inc. Announces Reverse Stock Split
22 Sep 2023 //
GLOBENEWSWIRE
Vaccinex Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
Vaccinex Reports 1Q 2023 FYR Results and Provides Corporate Update
15 May 2023 //
GLOBENEWSWIRE
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD
25 Apr 2023 //
GLOBENEWSWIRE
Vaccinex ActivMAb application published in Nature Communications
12 Apr 2023 //
GLOBENEWSWIRE
Vaccinex Reports 2022 Financial Results
03 Apr 2023 //
GLOBENEWSWIRE
Vaccinex Announces Private Placement with Commitments of $5.0 Million
03 Apr 2023 //
GLOBENEWSWIRE
Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference
23 Mar 2023 //
GLOBENEWSWIRE
Vaccinex Announces Initiation of Phase Ib/2 Study to Evaluate Pepinemab
21 Mar 2023 //
GLOBENEWSWIRE
Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment
09 Mar 2023 //
GLOBENEWSWIRE
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody
09 Jan 2023 //
GLOBENEWSWIRE
